Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821). On January 8, 2025, ...
Zacks.com on MSN14h
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy DesignationDenali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...
The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...
A breakthrough in prostate cancer treatment has seen a drug shrink tumours in men with advanced disease ...
A German research team’s discoveries about autoimmune diseases are opening up new possibilities for patients with lupus and ...
Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...
A team from the Institute of Cancer Research, London, found NXP800 slowed the growth of prostate cancer cells, including ...
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...
Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...
My tailored session combined life coaching, hypnotherapy, meditation, breathwork, vision-crafting skills and strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback